Britain’s FTSE 100 recorded its third consecutive weekly decline after closing 43 points lower, down 0.4%, at 10,233.07 on Friday. The more domestically focused FTSE 250 also ended weaker, slipping 0.15% to close
Britain’s FTSE 100 recorded its third consecutive weekly decline after closing 43 points lower, down 0.4%, at 10,233.07 on Friday. The more domestically focused FTSE 250 also ended weaker, slipping 0.15% to close
The Times: Asian equity markets have soared to record highs overnight amid rising hopes of a peace deal in the Middle East. President Trump has said there is a “very good
Rift Helium (RIFT) admitted to AIM on 22 Apr 2026 after raising £8.1m from a placing of 80.855m new shares at 10p, leaving 134,142,041 shares outstanding and a market capitalisation of
hVIVO plc (HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announced its audited results for the year ended 31 December 2025. Revenue of
Block Energy (BLOE), the development and production company focused on Georgia, is pleased to announce that it has executed a binding Framework Agreement with Zhijiang Sanning Energy Co. Ltd for the
The FTSE 100 ended the week on a high, gaining 43 points to close at 10,446. The mid-cap FTSE 250 also finished on a positive note, rising 0.52% to 23,427.27.
The week closed with the UK equities edging higher. In London, the FTSE 100 rose 0.5% to finish at 10,224 points, while the FTSE 250 was little changed at 23,253.
hVIVO plc (HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, provided a trading update for the year ended 31 December 2025
The FTSE 100 ended the week at a new record high. London’s benchmark index advanced 0.8% to close at 10,124.60 points, with gains led by Glencore. Precious metals edged higher after data pointed
2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty.
The biotechnology market has delivered a mixed landscape in 2025, shaped by shifting investor sentiment, ongoing regulatory pressures, and the continued search for differentiated clinical assets. Against this backdrop several
2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty.